Outlook Therapeutics, Inc. (OTLK) Insider Trading Activity

NASDAQ$0.4597
Market Cap
$111.99M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
53 of 849
Rank in Industry
38 of 491

OTLK Insider Trading Activity

OTLK Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$8,117,771
10
100
Sells
$0
0
0

Related Transactions

Sukhtian Ghiath M.
2
$7.5M
0
$0
$7.5M
HILZINGER KURT Jdirector
1
$176,520
0
$0
$176,520
Sukhtian Faisal Ghiathdirector
2
$150,002
0
$0
$150,002
Jahr Robert CharlesChief Executive Officer
1
$150,000
0
$0
$150,000
KENYON LAWRENCE AChief Financial Officer
1
$100,000
0
$0
$100,000
Haddadin Yezan Muntherdirector
2
$39,105
0
$0
$39,105
THURMAN RANDY Hdirector
1
$2,145
0
$0
$2,145

About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and …

Insider Activity of Outlook Therapeutics, Inc.

Over the last 12 months, insiders at Outlook Therapeutics, Inc. have bought $8.12M and sold $0 worth of Outlook Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Outlook Therapeutics, Inc. have bought $11.37M and sold $1.09M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Sukhtian Ghiath M. () — $7.5M. HILZINGER KURT J (director) — $176,520. Sukhtian Faisal Ghiath (director) — $150,002.

The last purchase of 151,515 shares for transaction amount of $150,000 was made by Jahr Robert Charles (Chief Executive Officer) on 2026‑08‑14.

List of Insider Buy and Sell Transactions, Outlook Therapeutics, Inc.

2026-08-14PurchaseJahr Robert CharlesChief Executive Officer
151,515
0.106%
$0.99
$150,000
-17.61%
2026-08-14PurchaseKENYON LAWRENCE AChief Financial Officer
101,010
0.0707%
$0.99
$100,000
-17.61%
2026-08-12PurchaseSukhtian Ghiath M.
2.53M
1.2154%
$0.99
$2.5M
-43.23%
2026-07-29PurchaseSukhtian Faisal Ghiathdirector
95,398
0.2431%
$1.05
$99,996
-36.02%
2026-06-02PurchaseHaddadin Yezan Muntherdirector
29,000
0.0721%
$0.83
$24,145
-15.18%
2026-05-28PurchaseSukhtian Ghiath M.
8.54M
16.4237%
$0.59
$5M
-5.66%
2026-05-27PurchaseSukhtian Faisal Ghiathdirector
122,174
0.2076%
$0.41
$50,006
+19.56%
2026-05-26PurchaseHILZINGER KURT Jdirector
400,000
0.7328%
$0.44
$176,520
+74.44%
2026-05-26PurchaseHaddadin Yezan Muntherdirector
34,000
0.0621%
$0.44
$14,960
+74.44%
2026-05-26PurchaseTHURMAN RANDY Hdirector
5,000
0.0089%
$0.43
$2,145
+74.44%
2024-09-26PurchaseKENYON LAWRENCE AChief Financial Officer
5,000
0.0216%
$5.69
$28,446
-68.75%
2024-04-15PurchaseSyntone Ventures LLC10 percent owner
714,286
2.6874%
$7.00
$5M
-35.27%
2024-03-28PurchaseHaddadin Yezan Muntherdirector
1,881.71
0.0143%
$11.82
$22,242
-49.58%
2024-03-07PurchaseEvanson JeffCHIEF COMMERCIAL OFFICER
62,484
0.0245%
$0.42
$26,243
-17.56%
2023-04-20SaleDagnon TerryChief Operations Officer
520,000
0.2181%
$1.14
$590,200
-62.27%
2023-01-20SaleEvanson JeffChief Commercial Officer
267,000
0.1196%
$1.11
$296,370
-0.92%
2023-01-19SaleEvanson JeffChief Commercial Officer
103,255
0.0462%
$1.22
$125,971
-10.00%
2023-01-18SaleEvanson JeffChief Commercial Officer
33,738
0.015%
$1.25
$42,173
-12.90%
2023-01-17SaleEvanson JeffChief Commercial Officer
27,162
0.0122%
$1.31
$35,582
-15.63%
2022-10-07PurchaseSukhtian Faisal Ghiathdirector
30,000
0.0135%
$1.29
$38,700
-9.92%
Total: 99
*Gray background shows transactions not older than one year

Insider Historical Profitability

82.26%
Sukhtian Ghiath M.
24617320
10.112%
$11.32M40
+92.17%
HILZINGER KURT Jdirector
423655
0.174%
$194,881.30350
Sukhtian Faisal Ghiathdirector
220972
0.0908%
$101,647.1260
+121.5%
Jahr Robert CharlesChief Executive Officer
151515
0.0622%
$69,696.9010
KENYON LAWRENCE AChief Financial Officer
106956
0.0439%
$49,199.7643
+17.42%
Haddadin Yezan Muntherdirector
66167
0.0272%
$30,436.8280
+115.65%
THURMAN RANDY Hdirector
5593
0.0023%
$2,572.7830
+247.3%
Mohan Pankaj
7064553
2.9019%
$3.25M14
Syntone Ventures LLC10 percent owner
1705438
0.7005%
$784,501.4830
+28.25%
Evanson JeffCHIEF COMMERCIAL OFFICER
808459
0.3321%
$371,891.1426
Dagnon TerryChief Operations Officer
653058
0.2683%
$300,406.6833
+8.57%
TRENARY C RUSSELL IIICEO and President
54925
0.0226%
$25,265.5030
+8.57%
Bahrt KennethChief Medical Officer
47120
0.0194%
$21,675.2012
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$5,552,811
165
5.84%
$106.2M
$16,280,851
76
1.48%
$118.27M
$4,898,715
46
40.75%
$114.69M
$130,095
43
45.19%
$111.24M
$47,438,336
33
-21.38%
$122.37M

OTLK Institutional Investors: Active Positions

Increased Positions29+53.7%3M+75.25%
Decreased Positions18-33.33%313,584-7.69%
New Positions9New718,761New
Sold Out Positions10Sold Out123,517Sold Out
Total Postitions65+20.37%7M+67.56%

OTLK Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vanguard Group Inc$886.002.1%1.34M+91,029+7.27%2025-09-30
Schonfeld Strategic Advisors Llc$472.001.12%715,170-649,639-47.6%2025-09-30
Blackrock, Inc.$244.000.58%369,734+29,838+8.78%2025-09-30
Geode Capital Management, Llc$202.000.48%306,295+40,664+15.31%2025-09-30
Susquehanna International Group, Llp$140.000.33%211,421+93,652+79.52%2025-09-30
Millennium Management Llc$128.000.3%194,583-143,988-42.53%2025-09-30
Commonwealth Equity Services, Llc$75.000.18%113,151+85,000+301.94%2025-09-30
Bank Of America Corp /De/$60.000.14%90,475+82,662+1,058.01%2025-09-30
Simplex Trading, Llc$59.000.14%89,241+89,241New2025-09-30
State Street Corp$50.000.12%75,302-10,150-11.88%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.